

Co-Diagnostics, Inc. Verifies Zika CoPrimer™ Test

SALT LAKE CITY, July 27, 2017 (GLOBE NEWSWIRE) — Co-Diagnostics, Inc. (NASDAQ:[CODX](#)) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, has completed principle design and verification of its Zika test built on the Company’s CoPrimer™ technology.

The Company’s patent-pending CoPrimer platform was specifically designed to dramatically reduce the occurrence of false positives in molecular diagnostics. With the in-house verification of the CoPrimer Zika test complete, Co-Diagnostics is preparing a performance evaluation with external validation partners in Central America. The studies should prove the accuracy of the test using locally-collected human samples and will also compare the CoPrimer iteration of the Zika test with the Company’s previous Zika test to confirm enhanced performance.

Co-Diagnostics CEO Dwight Egan remarked, “Since the presence of the Zika virus in the Americas was confirmed over 18 months ago, concern has grown substantially in this hemisphere over the danger it poses to unborn children and others. The final step that will allow sale of our upgraded Zika test throughout these countries is adding the necessary data to our CE marking documentation to show that it meets our high standards of quality and performance. We are eager to bring this version of our Zika test to market throughout Latin America and the Caribbean region.”

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Disclaimer:

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Co-Diagnostics
Investor Relations, 801-438-1036
info@codiagnosics.com

<https://news.codiagnosics.com/2017-07-27-Co-Diagnostics-Inc-Verifies-Zika-CoPrimer-TM-Test>